Daxor logo

DXR - Daxor News Story

$10.74 -0.3  -3.0%

Last Trade - 9:10pm

Micro Cap
Market Cap £33.0m
Enterprise Value £34.1m
Revenue £200k
Position in Universe 6092nd / 7405


Thu 22nd July, 2021 1:30pm
For best results when printing this announcement, please click on link below:

NEW YORK, July 22, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR),
the global leader in blood volume measurement technology, announces today that
it has signed a non-government distribution agreement with Concordance
Healthcare Solutions, one of the largest independent healthcare distributors
in the U.S. Daxor and Concordance will work together to provide Daxor’s
BVA-100(®) (Blood Volume Analyzer) diagnostic blood test to healthcare
facilities nationally, driving the use of blood volume measurement to help
guide precise, individualized volume management in a wide variety of medical
conditions including heart failure and critical care.

“Partnering with Concordance will accelerate Daxor's growing sales, allowing
our technology to reach even more healthcare systems,” said Michael
Feldschuh, Daxor’s CEO and President. “Combining our sales and marketing
efforts will facilitate awareness, adoption and integration of our much-needed
and valuable test into standard of care, leading to better outcomes and
improvement of the quality of life for patients.”

“Partnering with Daxor, the dedicated leader in blood volume measurement
technology, to distribute the BVA-100 supports our purpose of ‘Positively
Impacting Lives’ by reducing readmissions, lowering healthcare costs and
improving the lives of our customer’s patients,” said Bill Muich,
Concordance’s Senior Director, Equipment Sales and Service. “The Daxor
BVA-100 will allow Concordance to offer a unique solution in the lab equipment
space benefiting both patients and providers.”

About Daxor Corporation

Daxor Corporation (NYSE: DXR) is the global leader in blood volume measurement
technology focused on blood volume testing innovation (organized as an
investment company with fully-owned innovative medical instrumentation and
biotechnology operations). We developed and market the BVA-100(®) (Blood
Volume Analyzer), the first diagnostic blood test cleared by the FDA to
provide safe, accurate, objective quantification of blood volume status and
composition compared to patient-specific norms. The BVA technology enhances
hospital performance metrics in a broad range of surgical and medical
conditions, including heart failure and critical care, by informing treatment
strategies, resulting in significantly improved multiple measures of patient
outcomes. Daxor's mission is to advance healthcare by enabling optimal fluid
management with blood volume analysis. Daxor’s vision is optimal blood
volume for all. For more information, please visit our website at Daxor

About Concordance Healthcare Solutions

Concordance Healthcare Solutions, an independent healthcare distributor
headquartered in Tiffin, Ohio, is built on over 175 years of combined industry
experience through the merger of three of the nation’s premier healthcare
distributors. Concordance spans the U.S. market with nineteen distribution
centers licensed in forty-eight states. Concordance delivers dynamic,
dependable service to the entire care continuum including Acute Care,
Community Health, Government, Home Care, Hospice, Laboratory, Long Term Care,
Primary Care and Surgery Centers. In addition, Concordance has experts
dedicated to emergency preparedness, 3PL, and reverse logistics, in addition
to offering comprehensive support for equipment, remodeling and construction
project needs. To learn more, visit: www.conc

Forward-Looking Statements

Certain statements in this release may include forward-looking statements
within the meaning of the Private Securities Litigation Reform Act of 1995,
including without limitation, statements regarding the impact of hiring sales
staff and expansion of our distribution channels. Forward-looking statements
are predictions, projections and other statements about future events that are
based on current expectations and assumptions and, as a result, are subject to
risks and uncertainties. Many factors could cause actual future events to
differ materially from the forward-looking statements in this release,
including, without limitation, those risk associated with our post-market
clinical data collection activities, benefits of our products to patients, our
expectations with respect to product development and commercialization
efforts, our ability to increase market and physician acceptance of our
products, potentially competitive product offerings, intellectual property
protection, FDA regulatory actions, our ability to integrate acquired
businesses, our expectations regarding anticipated synergies with and benefits
from acquired businesses, and additional other risks and uncertainties
described in our filings with the SEC. Forward-looking statements speak only
as of the date when made. Daxor does not assume any obligation to publicly
update or revise any forward-looking statements, whether as a result of new
information, future events or otherwise.

Daxor Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR


GlobeNewswire, Inc. 2021
© Stockopedia 2022, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.